About PreOmics - The founder team of PreOmics started working on optimized LC-MS proteomic workflows at the Matthias Mann lab in 2010. After establishing an optimized and easier sample preparation process in 2014, Dr. Nils A. Kulak together with Dr. Garwin Pichler set forth to validate their technologies with external laboratories and researchers. With a lot of support of proteomics experts, engineers and industry designers, they made their first product ready-for-market. The PreOmics team won several awards for their business idea, were supported by various accelerator programs and established their company in the beginning of 2016. They are now located at the IZB in Martinsried just south of Munich.

Champion! PreOmics advisors and investors

Meet those supporting PreOmics growth and innovation


High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With around EUR900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge almost 600 start-ups since2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in the fields of digital business models, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected over EUR 2.5 billion into the HTGF portfolio via more than 1,600 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies.

Investors in the public-private partnership include the Federal Ministry of Economics and Energy, KfW Capital, theFraunhofer-Gesellschaft and 32 companies.
Think.Health Ventures invests in companies in the healthcare and life science sectors. Through active support and a broad network, the portfolio companies are supported and promoted in their development. The Think.Health Ventures team has many years of experience inhospital management, healthcare and M&A transactions.
TBA is the investment company in startups of the South Tyrolean entrepreneur Harald Oberrauch, owner of the two global companies Durst Phototechnik AG and Alupress AG.The TBA was founded in 2014 with the aim of supporting technology-oriented start-ups. TBA invests in passionate founders with courage and perseverance. The investment focus is on early-stage startups from the deep-tech sector (including biotech and medtech) with a B2B business model.As part of our angel investments, we also offer startups a sparing partnership and support through our know-how and our networks.
Business Angel Consortium
Great network of very experienced and entrepreneurial business angels.

Advisory Board

Dr. Andreas Jenne
Andreas is a co-founder of SciRhom GmbH and served as Chairman of the Board before joining the company’s management team in 2020. Andreas has more than 20 years of executive management experience in the life sciences industry and co-founded six biotechnology companies. Prior to joining SciRhom GmbH he was the CEO of RSP Systems A/S, a Danish medical device company focusing on non-invasive diagnostics. Further professional stations include CEO positions at Kinaxo GmbH (a proteomics service provider sold to Evotec in 2011) and NEO New Oncology AG (a cancer diagnostics company sold to Siemens Healthcare in 2016). Andreas holds a Ph.D. in Chemistry from the Ludwig-Maximilians-University in Munich.
Dr. Fabian Mohr
Dr. Fabian Mohr holds a PhD in molecular medicine and supports the HTGF Life Science practice as investment manager.Before joining HTGF, Fabian was a project lead in strategy consulting for product innovation, data driven business models, M&A and evaluation of new technology use-cases in the Life Science and Medical Technology industry.
Dr. Michael Ruoff
Dr. Michael Ruoff is a partner at Think.HealthVentures, a boutique investor specializing in healthcare startups. The trained lawyer and business graduate has a broad range of experience in corporate finance, M&A, private equity and venture capital. For about 10 years, he has been predominantly active as an entrepreneur.
Dr. Ulrich Schriek
Dr. Schriek joined QIAGEN in 1997. He served as Head of Corporate Business Development& Intellectual Property & Litigation and Senior Vice President at Qiagen GmbH until 2015. Dr. Ulrich Schriek is now Senior Advisor to Qiagen since July 2015. Prior to joining QIAGEN, Dr. Schriek held several sales and marketing positions at Pharmacia Biotech, where he served as Global MarketingDirector. Dr. Schriek graduated with a Master's degree in Science and obtained his Ph.D. in Biology from the Ruhr Universität Bochum in Germany. He worked for the World Economic Forum´s Technology Pioneers Selection Committee 2013 and2014 and is since 2011 member of the Investment Committee K2 at the High Tech Gründer Fond (HTGF).
Martin Spitznagel
Martin has been an entrepreneur his entire life with companies in Germany, Switzerland and the US. He strongly believes that biotechnology will provide many enabling technologies to solve major social challenges of the future. He’s currently the founder and CEO of an industrial biotech company that aims at increasing sustainability and innovation within the global mining, agriculture and construction industry. Martin holds a M.S. in Mechanical Engineering with specialisation in robotics and control systems from ETH Zurich and UC Berkeley. He further received an MBA from IE Business School in Madrid, where he also gives lectures on entrepreneurship.